Skip to content

Study · Randomized controlled trial · n = 18 · 2026

4 results

Promoting self-compassion meditation with intranasal oxytocin in borderline personality disorder: a pilot study.

Arqueros M, Soler J, Almenta D, Soria-Madrid A, Schmidt C, Pascual JC

Psychiatry research17 Jun 2026

PMID42372695 (opens in a new tab)DOI10.1016/j.psychres.2026.117294 (opens in a new tab)PepBankPUB-42372695
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with borderline personality disorder, intranasal oxytocin was associated with higher endpoint imagination scores of compassion practice quality than placebo.

    In plain wordsIn adults with borderline personality disorder, oxytocin was linked to higher imagination scores during compassion meditation than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseCompassion practice quality, imagination dimension
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU · intranasal · five weekly sessionsAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin was associated with higher endpoint scores on the imagination dimension of compassion practice quality.
    2 context sentences
    Summary · context
    In this pilot study, 18 individuals with BPD received intranasal oxytocin (24 IU) or placebo prior to a guided compassion-based meditation practice over five weekly sessions.
    Summary · context
    Endpoint differences were examined using ANCOVA models controlling for baseline values.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with borderline personality disorder, intranasal oxytocin did not change the total compassion practice quality score compared with placebo.

    In plain wordsIn adults with borderline personality disorder, oxytocin did not change the total compassion practice score compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCompassion practice quality, total score
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU · intranasal · five weekly sessionsAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed for the total score or the somatic dimension, and no adverse effects related to oxytocin administration were reported.
    2 context sentences
    Summary · context
    In this pilot study, 18 individuals with BPD received intranasal oxytocin (24 IU) or placebo prior to a guided compassion-based meditation practice over five weekly sessions.
    Summary · context
    Endpoint differences were examined using ANCOVA models controlling for baseline values.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with borderline personality disorder, intranasal oxytocin did not change the somatic dimension of compassion practice quality compared with placebo.

    In plain wordsIn adults with borderline personality disorder, oxytocin did not change the body-feeling part of compassion practice compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCompassion practice quality, somatic dimension
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24 IU · intranasal · five weekly sessionsAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed for the total score or the somatic dimension, and no adverse effects related to oxytocin administration were reported.
    2 context sentences
    Summary · context
    In this pilot study, 18 individuals with BPD received intranasal oxytocin (24 IU) or placebo prior to a guided compassion-based meditation practice over five weekly sessions.
    Summary · context
    Endpoint differences were examined using ANCOVA models controlling for baseline values.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with borderline personality disorder, no adverse effects related to intranasal oxytocin were reported.

    In plain wordsIn adults with borderline personality disorder, no side effects linked to oxytocin were reported.

    Peptide
    Oxytocin
    Outcome
    No significant changeAdverse effects related to oxytocin
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    24 IU · intranasal · five weekly sessionsAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed for the total score or the somatic dimension, and no adverse effects related to oxytocin administration were reported.
    2 context sentences
    Summary · context
    In this pilot study, 18 individuals with BPD received intranasal oxytocin (24 IU) or placebo prior to a guided compassion-based meditation practice over five weekly sessions.
    Summary · context
    Endpoint differences were examined using ANCOVA models controlling for baseline values.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.